Clinical development failure or delay
Budoprutug and CLYM116 are still in development and may not show sufficient safety or efficacy.
- Scope
- Lead programs in pMN, ITP and SLE
- Materiality
- high
Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing antibody therapeutics for immune-mediated diseases. Its pipeline is built through acquisitions and in-licensing, with lead programs budoprutug and CLYM116 aimed at B-cell and APRIL biology across multiple autoimmune indications.
15.16
15.16
| % | |
|---|---|
| Lead antibody candidate: budoprutug | 50% Clinical-stage anti-CD19 monoclonal antibody being developed for immune-mediated diseases. |
| Second antibody candidate: CLYM116 | 30% Anti-APRIL monoclonal antibody licensed for development and commercialization outside Greater China. |
| Clinical development programs | 20% Preclinical and clinical work across pMN, ITP, SLE and other immune-mediated indications. |
Climb Bio does not yet sell approved products, so its near-term 'customers' are clinical investigators, trial sites,...
- Clinical investigators and trial sitesprimary
They run the company’s studies and generate the data needed to advance budoprutug and CLYM116.
- Regulatorsprimary
FDA and other agencies evaluate the clinical package and determine whether the candidates can be approved.
- Physicians treating autoimmune diseaseprimary
Future prescribers for pMN, ITP and SLE if the products reach market; they will choose based on efficacy and safety.
- Third-party payorssecondary
Insurers and government payors will determine coverage and reimbursement, which will shape uptake.
Climb Bio is headquartered in the United States and conducts its development activities through a U.S...
- •Headquartered in Wellesley Hills, Massachusetts, United States
- •Clinical development and corporate functions are U.S.-based
- •Budoprutug rights are worldwide except oncology
- •CLYM116 rights exclude mainland China, Hong Kong, Macau and Taiwan
- •No approved products and no disclosed product revenue yet
The company’s strategy is to build a focused pipeline in immune-mediated diseases using assets with clear biological...
01
Advance budoprutug in pMN, ITP and SLEshort-term
These indications have a strong mechanistic rationale and could validate the lead asset across multiple autoimmune markets.
02
Develop CLYM116 as a second B-cell targeted programmedium-term
Adds pipeline depth and diversifies the company beyond a single lead asset.
03
Secure external funding and partnershipsshort-term
The company has no product revenue and will need capital to fund trials and commercialization.
Climb Bio is exposed to the classic risks of an early-stage biotech: clinical failure, regulatory delay, and the need...
Need for additional capital
The company has no product revenue and expects continued operating losses, so funding needs are ongoing.
- Scope
- Equity dilution or unfavorable financing terms
- Materiality
- high
Competitive pressure in autoimmune disease
Large pharma and biotech peers may launch superior or earlier therapies, limiting market share and pricing.
- Scope
- Immune-mediated disease markets
- Materiality
- high
Manufacturing and supply dependence on CDMOs
The company does not own manufacturing facilities and relies on third parties for clinical and future commercial supply.
- Scope
- Nonclinical and clinical supply chain
- Materiality
- medium
Research and development accruals
Affects operating loss, accrued liabilities and period-to-period comparability
Stock-based compensation
Can materially increase non-cash operating expense
Impairment and valuation of acquired/licensed assets
Could affect intangible assets and future earnings
: 28.4.2026